WillItSurvive
Pharma and healthcare groups · United States

Baxter International

baxter.com ↗

Baxter makes IV fluids, infusion pumps, and hospital-critical medical hardware worldwide.

Protection under test
Assessed 20 July 2026 · Evidence as of 20 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 20 July 2026 · Checkable from July 30, 2026 · Every call on the record Checkpoint: Q2 2026 earnings call, where Baxter must show promised margin recovery and Novum IQ recall progress
The call

Baxter's installed base and hospital contracts still hold, but a recalled flagship pump and a widening net loss leave the turnaround unproven.

Baxter makes infusion pumps and other hospital equipment that doctors rely on every day. It is hard to replace because hospitals sign multi-year contracts, the devices need FDA approval, and Baxter has 1.5 million pumps already installed in hospitals. However, the company is losing money right now, its main new pump is being recalled, and rivals like Becton Dickinson and ICU Medical are taking customers away. The biggest question is whether Baxter can fix its problems and return to profit by mid-2026, or whether hospitals will keep switching to competitors while the company struggles.

Why
01
AI pressure: None apparent. Baxter sells regulated hardware and IV fluids, a space generative AI does not directly replace or disrupt yet. Could AI do the core job? Unlikely.
02
Bigger players: Becton Dickinson, ICU Medical, Fresenius Kabi, B. Braun, Terumo. BD already holds over 15% of outpatient oncology infusion share, and Novum IQ pump recalls give hospitals reason to switch vendors. Could a giant copy it? No, they are blocked.
03
What protects it. 1.5 million-plus installed pumps, multi-year hospital contracts, and FDA clearance barriers make switching slow and costly.
What would change this call
FDA status of Novum IQ Large Volume Pump recall by late 2026. shows whether the flagship infusion platform's safety issues are resolved or worsening.
Q2 2026 earnings call results on July 30, 2026. shows whether promised margin recovery and organic growth actually materialize.
Rulings or disclosures in the Northern District of Illinois securities case (No. 25-cv-14712). shows whether Novum IQ disclosure practices are found legally deficient.
Key numbers
  • TTM net loss around $957M (2026-03-31)
  • Q1 2026 organic sales down 1% (2026-03-31)
  • Market cap near $11.1-11.7B (2026-07-14)
Named risks
  • Novum IQ infusion pump recalls (Class 1 and Class 2, 2025-2026) could escalate into platform withdrawal. Severity: high
  • Securities class action filed December 2025 alleging misleading Novum IQ disclosures from Feb 2022 to Oct 2025. Severity: high
  • Negative TTM net income (~-$957M) and negative organic growth (-1% Q1 2026) signal unproven turnaround. Severity: high
  • Tariff headwinds (~$80M full year) and injectables supply constraints threaten reiterated FY2026 guidance. Severity: medium
  • July 2026 Duo-Vent IV set early alert could add to recall burden on top of Novum IQ issues. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Becton Dickinson (BD)losing toBD holds over 15% share in outpatient oncology infusion as of November 2025, market leader position
ICU MedicalcontestingCompetes directly in infusion systems; recall risk on Baxter Novum IQ pumps raises defection risk since 2025
Fresenius Kabi / Fresenius Medical CarecontestingLongtime rival with history of dialysis-machine patent litigation against Baxter
B. BrauncontestingGerman peer competing across IV solutions and infusion systems markets
Questions people ask
Is Baxter International profitable in 2026?
No. Baxter's trailing twelve month net income was roughly negative $957M as of Q1 2026 (March 31, 2026), and 2024 posted a net loss of about $649M, though Q1 2026 adjusted EPS of $0.36 beat consensus of $0.31.
Is Baxter laying off workers?
Headcount fell to approximately 37,500 as of December 31, 2025, down 1.3% from 38,000 in 2024, and down 36.7% from 60,000 in 2023, mostly due to the Vantive kidney care divestiture rather than broad layoffs.
Could AI replace Baxter's core business?
Unlikely soon. Baxter's value sits in FDA-regulated hardware like infusion pumps and IV fluids, with over 1.5 million connected devices in use (Baxter-claimed, as of February 2026) and multi-year hospital contracts; AI mainly threatens thin software/analytics layers, not the physical product moat.
Who is Baxter's biggest competitor?
Becton Dickinson (BD) holds over 15% share in outpatient oncology infusion as of November 2025, making it a leading rival alongside ICU Medical, Fresenius Kabi, B. Braun, and Terumo in infusion and hospital device markets.
Is Baxter facing lawsuits over its infusion pumps?
Yes. A securities class action was filed December 3, 2025 in the Northern District of Illinois (case No. 25-cv-14712) alleging misleading disclosures about the Novum IQ Large Volume Pump between February 2022 and October 2025.
What is Baxter's debt reduction plan?
Baxter is targeting net leverage near 3x by the end of 2026, using proceeds from the $3.8 billion Vantive kidney care divestiture to Carlyle, which closed in January 2025, according to Q1 2026 guidance issued April 30, 2026.
Timeline
  • 2026-07-19FDA early alert on Baxter Duo-Vent IV sets over air-bubble issue, no serious injuries reported
  • 2026-07-14Zacks downgrades Baxter to Strong Sell, trims FY2026 EPS estimate to $1.83
  • 2026-07-08Evercore ISI raises Baxter price target to $24 from $22
  • 2026-04-30Baxter reports Q1 2026 results: sales up 3% reported, down 1% organic, adjusted EPS $0.36
  • 2026-01-13Baxter launches Dynamo Series smart stretcher in US at JPM Healthcare Conference
  • 2025-12-21FDA issues correction for Baxter Novum IQ Large Volume Pumps over software mismatches
  • 2025-12-11Baxter presents UTMB Health data on over 1 million Spectrum IQ infusions with EMR integration
  • 2025-12-03Securities class action filed against Baxter in N.D. Illinois over Novum IQ disclosures
  • 2025-08-13FDA issues Class 1 recall for Baxter Novum IQ pump over underinfusion risk
  • 2025-01Baxter closes $3.8 billion Vantive kidney care divestiture to Carlyle
Revision history
20 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
SolventumNovo NordiskBristol-Myers Squibb
More in Pharma and healthcare groups →
Sources